Premium
Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII‐Fc Fusion Protein
Author(s) -
Groomes Charles L.,
Gianferante David M.,
Crouch Gary D.,
Parekh Dina S.,
Scott David W.,
Lieuw Kenneth
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25874
Subject(s) - medicine , titer , recombinant dna , fusion protein , immune system , immune tolerance , immunology , pharmacology , antibody , gene , biochemistry , chemistry
The development of inhibitors toward factor VIII (FVIII) is a common and serious complication of hemophilia A (HA) therapy. Patients with hemophilia who develop inhibitors often undergo time‐ and resource‐intensive immune tolerance induction (ITI) protocols. We report a 15‐month‐old male with severe HA and a high‐titer inhibitor that occurred while receiving prophylactic treatment with recombinant FVIII (rFVIII), in whom significant inhibitor titer reduction was achieved with thrice weekly infusions of a new, prolonged half‐life rFVIII‐Fc fusion protein product (trade name Eloctate ). Further studies are warranted to explore the potential of Eloctate in ITI protocols.